(San Diego, CA) — A new, experimental drug lowers production of a toxic protein blamed for the development of Alzheimer’s disease.
The drugmaker Pfizer presented results of early stage testing at the annual Clinical Trials on Alzheimer’s Disease Conference in San Diego yesterday.
Pfizer tested the drug on more than 80 healthy volunteers and production of the toxic protein decreased by as much as 59-percent.
It’s the first drug of its kind to come out of early-stage research.
The next step will be testing the drug on people with Alzheimer’s.
Loading ...